Nasdaq GlobeNewswire

LifeSci Advisors Continues Expansion of U.S. Team with Appointment of Jeremy Feffer

Del

NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, LLC (the "Company" or "LifeSci"), the leading international investor relations and corporate communications firm dedicated to the life sciences sector, today announced the appointment of Jeremy Feffer as Managing Director.  Mr. Feffer will serve as a Relationship Manager and will contribute to managing new and existing client relationships in the medtech and biotech industries.

Jeremy brings 15 years of experience in healthcare to LifeSci, both as a sell-side equity research analyst and as an investor relations advisor. He covered Medical Devices and Diagnostics companies across the entire market cap spectrum as an analyst at Cantor Fitzgerald and Oppenheimer.  He began his career covering Healthcare Services at Bank of America.  As the founder of Whalebone Advisory, Jeremy built extensive experience developing and executing investor relations strategies for pre-IPO and publicly-traded healthcare companies and counseling senior executives on Wall Street engagement, including capital markets activities, guidance philosophy, earnings preparation, and corporate access plans.  Jeremy earned an MBA in Finance from the Leonard N. Stern School of Business at New York University, a Diploma in Economics from the London School of Economics, and a BA in Economics and Political Science from the University of Chicago.

Jeremy presently serves on the boards of the Edgemont Community Council and of the Fraternal Order of Bendin-Sosnowicer. He lives in Westchester with his wife and two children.

"We are pleased to add Jeremy to our growing team," said Michael Rice, President and Co-Founder of LifeSci Advisors. "He is a capital markets and investor relations expert with 15 years of experience in the Life Sciences sector.  We look forward to leveraging Jeremy's expertise and expansive network of investor contacts as we continue to attract top talent to provide counsel and support our client companies."

"I am thrilled to join this extraordinary team of talented individuals that LifeSci has built," said Mr. Feffer. "I look forward to helping the leading integrated healthcare investor relations firm expand its presence into Medical Devices and Diagnostics."

LifeSci has offices in Israel, UK and Switzerland, as well as multiple North American locations. The firm's capabilities include Corporate Access, Equity Research, Corporate Communications, KOL Events, Corporate Governance, Capital Markets Solutions, and Public Relations.

LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.

LifeSci Partners (www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.

For further information, please contact:

Michael Rice
Founding Partner
LifeSci Advisors, LLC 
(646) 597-6979




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Barefoot Networks Teams Up with Western Digital and Università della Svizzera italiana to Showcase In-Network Consensus for Use with Storage Class Memory and P424.9.2018 09:00Pressemelding

Barefoot Tofino™ Used in P4 Implementation for Low Latency Storage Class Memory Access is Presented at the P4 European Workshop CAMBRIDGE, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- P4 European Workshop —At the P4 European Workshop (P4EU 2018), Barefoot Networks and researchers from Western Digital and Università della Svizzera italiana (USI), with support from Xilinx and STORDIS, will today present a new breakthrough for providing in-network high-performance fault tolerance for Storage Class Memory (SCM) access using the P4 programming language. The demonstration uses a P4 program implementation developed by Western Digital and USI using Barefoot’s 6.5Tb/s Tofino™ switch ASIC. Programmable forwarding plane technology is enabling network owners to create and deliver value by accelerating application performance. One of the ways this is achieved is by offloading network functions that are run on servers or appliances onto switches. In addition to performing all standard switch a

4D Announces Positive Data From Phase 1b Study of Thetanix in Paediatric Crohn's Diseases Patients and Publication of Studies Showing Strong Efficacy of Thetanix in Preclinical Models of IBD24.9.2018 08:00Pressemelding

LEEDS, United Kingdom, Sept. 24, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line results for its Phase 1b study of Thetanix in paediatric patients with Crohn’s disease. The study achieved its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile. The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 subjects aged 16-18 with Crohn’s disease. In the single-dose phase, eight subjects were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 subjects were given either Thetanix or placebo twice daily for seven consecutive days. The Company also announces the publication of data demonstrating the efficacy of Thetanix in pre-clinical models of inflammatory bowel disease (IBD). The data, published in the journal

Researchers, Survivors, Advocates and Physicians Convene to Discuss Innovations in Lung Cancer Research, Treatment and Advocacy at the Largest-Attended World Conference on Lung Cancer24.9.2018 01:00Pressemelding

TORONTO, Sept. 23, 2018 (GLOBE NEWSWIRE) -- Patients, survivors and advocates joined researchers and physicians from across the globe to discuss the future of lung cancer at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. The conference’s first press briefing highlighted the record-breaking number of registered attendees (over 7,300), reviewed patient-caregiver communities working to accelerate research, evaluated survey data on the emotional needs of lung cancer survivors and underscored the impact of comprehensive genomic profiling on patient care. The press conference opened with a welcome message from conference co-presidents Natasha B. Leighl, M.D., BSc, MSc; Andrea Bezjak, M.D., FRCPC, MSc; and Gail Darling M.D., FRCSC, who have worked tirelessly to make this year’s conference in Toronto highly successful. Oncogene-driven patient-caregiver communities creating new paradigm for non-small cell lu

Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet21.9.2018 16:00Pressemelding

SpiceJet becomes the first airline to take advantage of the Q400 aircraft’s increased profit potential TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft. “We are excited to induct the 90-seat Q400 aircraft into our fleet,” said Ajay Singh, Chairman and Managing Director, SpiceJet. “The additional seats and performance improvements will result in substantial reduction in unit costs and also we will enable us to address our market needs in the regional space.” “The delivery of the first 90-seat Q400 aircraft showcases the commitment of Bombardier’s Q Series turboprop program to respond to customer requirements as they address traffic growth in regional markets,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “I thank and congratul

Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16Pressemelding

Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added

Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12Pressemelding

Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom